Li YF, Ren Q, Sun CH, Li L, Lian HD, Sun RX, Su X, Yu H. Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients. World J Diabetes 2022; 13(7): 532-542 [PMID: 36051431 DOI: 10.4239/wjd.v13.i7.532]
Corresponding Author of This Article
Qian Ren, MD, Associate Chief Physician, Department of Ophth-almology, Shijiazhuang City People’s Hospital, No. 365 Jianhua South Street, Yuhua District, Shijiazhuang 050031, Hebei Province, China. qr31535@163.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jul 15, 2022; 13(7): 532-542 Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients
Yun-Fei Li, Qian Ren, Chao-Hui Sun, Li Li, Hai-Dong Lian, Rui-Xue Sun, Xian Su, Hua Yu
Yun-Fei Li, Qian Ren, Chao-Hui Sun, Li Li, Rui-Xue Sun, Xian Su, Hua Yu, Department of Ophthalmology, Shijiazhuang City People’s Hospital, Shijiazhuang 050031, Hebei Province, China
Hai-Dong Lian, Department of Ophthalmology, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi 832061, Xinjiang Uygur Autonomous Region, China
Author contributions: Li YF and Yu H designed this study; Li YF wrote this manuscript; Li YF, Ren Q, Sun ZH, Li L, Lian HD, Sun RX, Sun X and Yu H were responsible for sorting the data; and all authors read and confirmed the revision of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Shijiazhuang City People’s Hospital Institutional Review Board (Approval No. 2017-22).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian Ren, MD, Associate Chief Physician, Department of Ophth-almology, Shijiazhuang City People’s Hospital, No. 365 Jianhua South Street, Yuhua District, Shijiazhuang 050031, Hebei Province, China. qr31535@163.com
Received: February 17, 2022 Peer-review started: February 17, 2022 First decision: April 17, 2022 Revised: April 26, 2022 Accepted: June 16, 2022 Article in press: June 16, 2022 Published online: July 15, 2022 Processing time: 143 Days and 20.3 Hours
ARTICLE HIGHLIGHTS
Research background
Diabetes is a serious public health concern in China, with 30% of patients developing retinopathy, and diabetic macular edema (DME) having the biggest impact on vision.
Research motivation
Compaq as an efficacious DME treatment, but whether it can inhibit neovascularization, reduce the perfusion area in the macular area, and improve microcirculation remains unclear.
Research objectives
This study aimed to investigate and compare the efficacy, mechanism, and differences between two anti-vascular endothelial growth factor (VEGF) drugs (Compaq and ranibizumab) in DME patients.
Research methods
Total 96 patients with DME were divided into two groups with different treatment modalities.
Research results
Marked efficient, effective, and invalid rates were 70.83% and 52.08%, 27.08% and 39.58%, and 2.08% and 8.33% in the Compaq and ranibizumab groups, respectively.
Research conclusions
Anti-VEGF drugs can effectively improve macular retinal thickness and macular choroidal thickness, without affecting microcirculation.
Research perspectives
This study was a preliminary clinical application study with a small sample size and a short follow-up period; hence, further studies are warranted to confirm our findings.
